Arcturus Therapeutics Holdings Inc. — News

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, Aug 6th and will also host a conference call and webcast at 4:30 pm Eastern Time on Aug 6, 2026. Arcturus Therapeutics Second Quarter 2026 Earnings.

businesswire.com - 2026-07-28 16:01:00

Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) and Arcturus Therapeutics (NASDAQ: ARCT - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability. Earnings and Valuation This table compares Zenas

defenseworld.net - 2026-07-28 01:15:17

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eleven analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, six have issued a buy recommendation and one has

defenseworld.net - 2026-07-26 01:59:19

Amova Asset Management Americas Inc. grew its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) by 12.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,288,935 shares of the biotechnology company's stock after purchasing an additional 262,347

defenseworld.net - 2026-07-21 03:16:02

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: Canaccord Genuity 46th Annual Growth Conference (Fireside Chat) Tuesday, August 11, 2026 (12:00 p.m. ET) Webcast link can be found under Investor Relations/Events section.

businesswire.com - 2026-07-20 16:01:00

Arcturus has dropped off enough to make it a net-cash stock - a stock trading for less its current asset value with all liabilities subtracted. A peer group of similar issues that I have rated here on Seeking Alpha has strongly outperformed the S&P 500 even through one of the strongest bull markets in history. This and the combination of a revenue generating asset portfolio and promising pipeline make Arcturus a compelling opportunity.

seekingalpha.com - 2026-07-20 11:38:03

Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

zacks.com - 2026-07-03 08:12:13

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is collaborating with Thermo Fisher Scientific Inc. (NYSE:TMO) to support the Phase 3 development and potential commercialization of ARCT-032, the company's investigational messenger RNA therapy for cystic fibrosis.

benzinga.com - 2026-07-02 11:32:58

Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare

gurufocus.com - 2026-07-02 08:00:00

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus' investigational mRNA therapy for Cystic Fibrosis. The collaboration will leverage Thermo.

businesswire.com - 2026-07-02 07:00:00

The world uses a lot of copper, but thanks to the energy transition and data centers, it'll need a lot more. Between now and 2050, we'll have to produce more copper than has been mined throughout all of human history, according to one study.

techcrunch.com - 2026-06-30 11:01:42

Arcturus Therapeutics Holdings Inc. (ARCT) Shareholder/Analyst Call Prepared Remarks Transcript

seekingalpha.com - 2026-06-05 13:42:56

Arcturus Therapeutics NASDAQ: ARCT President and CEO Joseph Payne outlined the company's messenger RNA programs, vaccine approvals and upcoming clinical milestones during a presentation at the Jefferies Global Healthcare Conference in New York.

marketbeat.com - 2026-06-05 05:03:36

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics will present at 2026 Jefferies Global Healthcare Conference.

businesswire.com - 2026-05-26 16:01:00

Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-08 00:31:15

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $0.52 per share a year ago.

zacks.com - 2026-05-07 18:55:20

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended March 31, 2026, and provided corporate updates. “Arcturus continues to advance its rare disease therapeutics portfolio. We have initiated enrollment of our 12‑week CF Phase 2 study in the first quarter of 2026, earlier.

businesswire.com - 2026-05-07 16:01:00